Tazloc contains wgat nd used for ehat purpose
Reading File
Searching the Web
Tazloc telmisartan tablet uses composition
Finding Sources
Reading File
Reading File
Here is a complete answer about Tazloc:
Tazloc - Composition and Uses
What It Contains
Tazloc is a brand name (manufactured by USV Ltd., India) for Telmisartan. It comes in different variants:
| Variant | Composition |
|---|---|
| Tazloc 20 / 40 / 80 | Telmisartan 20 mg / 40 mg / 80 mg |
| Tazloc-H | Telmisartan + Hydrochlorothiazide (a diuretic) |
| Tazloc-AM | Telmisartan + Amlodipine (a calcium channel blocker) |
| Tazloc-R | Telmisartan + Ramipril (an ACE inhibitor) |
What is Telmisartan?
Telmisartan is an Angiotensin II Receptor Blocker (ARB). It is a nonpeptide, noncompetitive blocker with high specificity and affinity for the AT1 receptor. It blocks angiotensin II from binding to its receptor, which prevents vasoconstriction and aldosterone release.
- Brand equivalents internationally: Micardis (by Boehringer Ingelheim)
- Starting dose: 40 mg once daily; usual dose: 40-80 mg/day
- Duration of action: 24 hours (may persist up to 7 days after stopping)
- Not dialyzable; no dose adjustment needed in kidney disease
- Minimal liver metabolism (<3%); eliminated mainly via bile
Uses (Indications)
- Hypertension (High Blood Pressure) - the primary indication; relaxes and widens blood vessels to lower BP
- Cardiovascular Risk Reduction - used in high-risk patients (those with coronary artery disease, stroke history, peripheral arterial disease, or type 2 diabetes with end-organ damage) to reduce the risk of heart attack, stroke, and cardiovascular death
- Diabetic Nephropathy - slows progression of kidney damage in type 2 diabetic patients
- Heart Failure - used in patients who are intolerant to ACE inhibitors
- Antipsychotic-related Hypertension - there is specific evidence supporting telmisartan in treating hypertension caused by antipsychotic medications
How It Works
Telmisartan blocks the AT1 (angiotensin II type 1) receptor, which:
- Prevents vasoconstriction (blood vessels stay relaxed)
- Reduces aldosterone secretion (less sodium and water retention)
- Lowers blood pressure and reduces afterload on the heart
Common Side Effects
- Dizziness / lightheadedness
- Elevated potassium (hyperkalemia) - especially in renal impairment
- First-dose hypotension
- Rarely: angioedema (much less common than with ACE inhibitors)
Contraindicated in pregnancy (can cause fetal harm).
Sources: Brenner and Rector's The Kidney; Lippincott Illustrated Reviews Pharmacology; Goodman & Gilman's Pharmacological Basis of Therapeutics
Ciplan la
Searching the Web
Cipla LA tablet composition uses India brand
Finding Sources
Finding Sources
Reading File
Finding Sources
Got it! Here is a full breakdown of Ciplar-LA:
Ciplar-LA - Composition and Uses
What It Contains
Ciplar-LA is a brand by Cipla Ltd., India containing Propranolol Hydrochloride in a Long-Acting (LA) / extended-release formulation.
| Variant | Composition |
|---|---|
| Ciplar-LA 40 | Propranolol HCl 40 mg (sustained release) |
| Ciplar-LA 80 | Propranolol HCl 80 mg (sustained release) |
The "LA" stands for Long-Acting - the drug is absorbed slowly over a 24-hour period, allowing once-daily dosing.
What is Propranolol?
Propranolol is the prototypical non-selective beta-blocker (β1 + β2 blocker). It blocks both β1 receptors (heart) and β2 receptors (lungs, blood vessels). It also has some membrane-stabilizing (local anesthetic) activity and may block serotonin receptors in the brain (relevant for migraine prevention).
Uses (Indications)
| Indication | Details |
|---|---|
| Hypertension | Lowers blood pressure by reducing heart rate and cardiac output |
| Angina Pectoris | Reduces myocardial oxygen demand by slowing the heart |
| Arrhythmias | Controls supraventricular tachycardias, atrial fibrillation/flutter |
| Migraine Prophylaxis | Reduces frequency and severity of migraines (likely via serotonin receptor blocking + beta blockade) |
| Essential Tremor | Reduces tremor; LA form preferred for convenience |
| Hyperthyroidism / Thyrotoxicosis | Controls tachycardia and symptoms of thyroid storm |
| Hypertrophic Obstructive Cardiomyopathy (HOCM) | Reduces outflow tract obstruction |
| Portal Hypertension | Prevents variceal bleeding (LA propranolol 60 mg once daily is a standard starting dose) |
| Anxiety / Situational Anxiety | Reduces palpitations and tremor in performance anxiety |
| Phaeochromocytoma | Used alongside alpha-blockers (never alone) |
Important Contraindications
- Asthma / COPD - β2 blockade causes bronchoconstriction (use with great caution or avoid)
- Bradycardia / Heart block
- Decompensated heart failure
- Diabetes (can mask hypoglycemia symptoms)
- Peripheral vascular disease
Key Pharmacology Points
- Non-selective beta-blocker (blocks both β1 and β2)
- Low oral bioavailability (extensive first-pass hepatic metabolism)
- LA form: absorbed over 24 hours, once-daily dosing
- Eliminated by the liver; dose reduction needed in hepatic impairment (not renal)
- Can cross blood-brain barrier (causes CNS side effects: fatigue, depression, nightmares)
Common Side Effects
- Bradycardia, hypotension
- Fatigue, lethargy
- Cold extremities
- Bronchoconstriction
- Depression, sleep disturbances
- Masking of hypoglycemia signs in diabetics
Sources: Katzung's Basic and Clinical Pharmacology 16e; Braunwald's Heart Disease; Yamada's Textbook of Gastroenterology; Cipla official product page
Tryptomer
Finding Sources
Searching the Web
Tryptomer tablet amitriptyline uses composition India
Reading File
Finding Sources
Finding Sources
Finding Sources
Here is a complete breakdown of Tryptomer:
Tryptomer - Composition and Uses
What It Contains
Tryptomer is a brand by Merind / Sun Pharma, India containing Amitriptyline Hydrochloride, a Tricyclic Antidepressant (TCA).
| Variant | Composition |
|---|---|
| Tryptomer 10 | Amitriptyline HCl 10 mg |
| Tryptomer 25 | Amitriptyline HCl 25 mg |
| Tryptomer 75 | Amitriptyline HCl 75 mg |
What is Amitriptyline?
Amitriptyline is one of the oldest and most widely used tricyclic antidepressants. Its pharmacological activity comes from multiple mechanisms:
| Mechanism | Effect |
|---|---|
| Blocks reuptake of Serotonin (5-HT) | Increases synaptic serotonin - antidepressant effect |
| Blocks reuptake of Norepinephrine (NE) | Increases synaptic NE - antidepressant + analgesic effect |
| Anticholinergic (muscarinic blockade) | Dry mouth, constipation, urinary retention, blurred vision |
| Antihistaminic (H1 blockade) | Sedation, weight gain |
| Alpha-1 adrenergic blockade | Orthostatic hypotension |
| Sodium channel blockade | Membrane stabilizing - analgesic + cardiac risk in overdose |
Its active metabolite is Nortriptyline (which is itself used as a separate drug).
Uses (Indications)
1. Psychiatric Indications
- Major Depressive Disorder - primary approved indication
- Anxiety disorders with depression
- Chronic depression
2. Pain Indications (very widely used)
- Neuropathic pain - diabetic neuropathy, post-herpetic neuralgia, nerve injury pain
- Fibromyalgia - first-line treatment per AWMF guidelines
- Chronic low back pain
- Interstitial cystitis / Bladder pain syndrome (via anticholinergic + analgesic effect)
3. Headache Prevention
- Migraine prophylaxis - reduces frequency and severity
- Chronic tension-type headaches
4. Other Uses
- Enuresis (bedwetting) in children (low doses)
- Irritable Bowel Syndrome (IBS) - low-dose pain modulation
- Insomnia - used off-label due to strong sedative effects
- Antipsychotic-related conditions - adjunct use
Dosing
| Indication | Typical Dose |
|---|---|
| Depression | 75-150 mg/day (in divided doses or at night) |
| Neuropathic pain | 10-75 mg at bedtime |
| Migraine prophylaxis | 10-75 mg at bedtime |
| Enuresis in children | 10-25 mg at bedtime |
Always started at a low dose (10-25 mg) at night and titrated slowly.
Important Warnings
- Cardiac toxicity - prolongs QT interval, causes conduction delays; dangerous in overdose (wide QRS, arrhythmias)
- Anticholinergic effects - avoid in elderly, benign prostatic hyperplasia (BPH), glaucoma
- Sedation - impairs driving/alertness
- Suicide risk - black-box warning; increased suicidal ideation in young patients initially
- Drug interactions - dangerous with MAOIs (serotonin syndrome); levels raised by SSRIs (via CYP2D6)
- Women have higher plasma levels and slower clearance than men (CYP2D6 difference)
- Overdose is potentially fatal - cardiac arrhythmias, seizures, coma
Contraindications
- Recent myocardial infarction
- Heart block / arrhythmias
- Concurrent MAOI use (within 14 days)
- Angle-closure glaucoma
- Urinary retention / BPH
Sources: Harrison's Principles of Internal Medicine 22e; Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Braunwald's Heart Disease; Rheumatology (Elsevier); Textbook of Family Medicine
Petril md
Finding Sources
Searching the Web
Petril MD clonazepam mouth dissolving tablet uses India
Reading File
Finding Sources
Finding Sources
Here is the complete breakdown of Petril MD:
Petril MD - Composition and Uses
What It Contains
Petril MD is a brand by Sun Pharma, India containing Clonazepam in an MD (Mouth Dissolving / Orally Disintegrating) tablet form - it dissolves on the tongue without water.
| Variant | Composition |
|---|---|
| Petril MD 0.25 | Clonazepam 0.25 mg |
| Petril MD 0.5 | Clonazepam 0.5 mg |
| Petril MD 1.0 | Clonazepam 1 mg |
| Petril MD 2.0 | Clonazepam 2 mg |
The MD formulation is particularly useful for patients who have difficulty swallowing (elderly, children, patients having seizures), and for faster/easier dosing.
What is Clonazepam?
Clonazepam is a high-potency, long-acting benzodiazepine. It is a positive allosteric modulator of the GABA-A receptor - it enhances the effect of GABA (the brain's main inhibitory neurotransmitter), increasing chloride ion influx and reducing neuronal excitability.
- Half-life: 20-60 hours (mean ~30 hours) - one of the longer-acting benzodiazepines
- Peak plasma: 1-4 hours after oral dose
- Potency: High potency (0.5 mg clonazepam = ~10 mg diazepam equivalent)
Uses (Indications)
| Indication | Details |
|---|---|
| Epilepsy / Seizures | Primary indication - controls multiple seizure types |
| - Absence seizures | Suppresses generalized absence (petit mal) epilepsy |
| - Myoclonic seizures | Effective for juvenile myoclonic epilepsy |
| - Focal (partial) seizures | Second-line adjunctive treatment |
| - Status epilepticus (early) | IV/rectal diazepam preferred, but clonazepam used |
| Panic Disorder | Reduces frequency and severity of panic attacks |
| Anxiety Disorders | Generalized anxiety, social anxiety (short-term) |
| Involuntary Muscle Spasms / Movement Disorders | Myoclonus, restless legs syndrome |
| REM Sleep Behaviour Disorder (RBD) | Considered first-line for RBD by AASM guidelines |
| Acute mania (adjunct) | Short-term add-on with mood stabilizers |
Mechanism of Action
Clonazepam binds to the benzodiazepine site on the GABA-A receptor, potentiating GABA-mediated inhibition throughout the CNS. This results in:
- Anticonvulsant effect (suppresses seizure spread)
- Anxiolytic effect (reduces limbic system excitability)
- Muscle relaxant effect (via spinal cord inhibition)
- Sedative/hypnotic effect
Dosing
| Indication | Typical Dose |
|---|---|
| Epilepsy (adults) | 0.5 mg 3x/day initially; up to 20 mg/day |
| Panic disorder | 0.25 mg twice daily; up to 4 mg/day |
| Anxiety | 0.5-2 mg/day in divided doses |
Always start low and titrate slowly; divided doses recommended.
Important Warnings
- Dependence and withdrawal - FDA black box warning: physical dependence can develop within days to weeks even at prescribed doses. Abrupt withdrawal can cause life-threatening seizures.
- Tolerance - long-term effectiveness (>9 weeks) not established in controlled trials
- Sedation - impairs driving, concentration
- Respiratory depression - especially dangerous with alcohol or opioids (FDA black box warning)
- Tapering - must be done gradually using hyperbolic dose reductions (not linear) to minimize withdrawal
- Switching to diazepam before tapering is an option for safer withdrawal management
Contraindications
- Severe liver disease
- Acute angle-closure glaucoma
- Myasthenia gravis
- Severe respiratory insufficiency
- Concurrent alcohol or CNS depressant use
Sources: The Maudsley Deprescribing Guidelines; Morgan and Mikhail's Clinical Anesthesiology 7e; Bradley and Daroff's Neurology in Clinical Practice; Kaplan and Sadock's Synopsis of Psychiatry
This is a shared conversation. Sign in to Orris to start your own chat.